To view the latest data, view 2020 Access & Savings Report
2019 Generic Drug and Biosimilars Access and Savings in the U.S.
The 11th annual edition of AAM’s Savings and Access Report quantifies how much money American patients and our health care system are saving because of generic and biosimilar alternatives to brand-name prescription and biologic medications. In 2018, generic savings totaled $293 billion. The “Case for Competition” in a nutshell: The presence in the market of FDA-approved safe and effective generic and biosimilar medicines saves more Americans more money every year.
Prescriptions filled
in the U.S. are
dispensed as generics
Generic share of
overall drug spending
in the U.S.
Generic prescriptions
filled at $20 or less
Generic
Jonnie – Heart Disease Patient, Oklahoma
Jonnie of Skiatook, OK, manages her heart condition with metoprolol ER, the generic form of the brand-name drug Toprol XL. Metoprolol costs around $6, which is 81 percent less than the average retail price of $33.10 for the brand. On the other hand, there is no generic of the estrogen replacement she takes, and what she pays for the brand product equals her car payment.
Medicare Savings
($2,254 per enrollee)
Medicaid Savings
($817 per enrollee)
In 2018, the per-state average savings realized by using generic prescription drugs was $5.7 billion. To view a full break down of generic savings by state and payer type, choose a state in the drop-down menu to download a one-page summary of how much that state saved from generic medicines.
When patients and providers opt for generic and biosimilar alternatives instead of brand-name prescription and biologic medications, the savings really add up—for any condition being treated. We also compiled data for common co-morbidities of each of these conditions.
Send a message to your lawmaker to
protect your generic savings.
Find out how to fix the U.S.-Mexico-Canada Agreement (USMCA).
Share this page now:
